Allergen immunotherapy: what’s new, what’s next?

Nelson, Harold S.

doi:10.1586/1744666x.2015.1062726

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AIT: Allergy immunotherapy AR/C: Allergic rhinitis with or without conjunctivitis FDA: US Food and Drug Administration SLIT: Sublingual immunotherapy safety data for off-label use. 7,8 Thus there is a need for more pediatric trials for SLIT products.…”

Section: Abbreviations Usedmentioning

confidence: 99%

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Kaur

Skoner

Ibrahim

et al. 2018

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

Section: Abbreviations Usedmentioning

confidence: 99%

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Kaur

Skoner

Ibrahim

et al. 2018

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…In addition, the FDA has set a high bar for efficacy—15% overall but 10% separation of the 95% confidence interval of the active product from the mean of the placebo. This means that large and therefore very expensive studies to narrow the confidence interval need to be performed 61…”

Section: Manufacturing Of Single Recombinant or Natural Allergens Andmentioning

confidence: 99%

Single recombinant and purified major allergens and peptides

Curin

Garib

Valenta

2017

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

During the last 25 years more than several hundred allergen sequences were determined, which led to a production of recombinant allergens that mimic biochemically and immunologically their natural counterparts. Especially in Europe, recombinant allergens are increasingly replacing allergen extracts in diagnosis of allergy. Despite many challenges, such as high cost of clinical trials and regulative issues, allergy vaccines based on recombinant allergens and peptides are being developed and will likely soon be available on the market.

show abstract

The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases

Nolte¹,

Maloney²

2018

Allergology International

View full text Add to dashboard Cite

Allergy immunotherapy (AIT) is a treatment option for respiratory allergy that is complementary to pharmacotherapy, with a distinct mechanism of action. Alternative methods to subcutaneous administration of AIT that enable patients to safely self-administer AIT is considered an unmet clinical need. The sublingual immunotherapy tablet (SLIT-tablet) is an orally disintegrating pharmaceutical formulation (oral lyophilisate) containing standardized allergens. SLIT-tablets have been developed for sublingual immunotherapy (SLIT) of cedar-pollen, grass-pollen, ragweed-pollen, tree-pollen, and house dust mite allergies. It is a once-daily tablet treatment to be self-administered after the first dose has been provided under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Once the first dose is adequately tolerated, subsequent doses may be self-administered. SLIT-tablets have proven efficacy for allergic rhinitis (AR) with and without conjunctivitis (C) and allergic asthma (AA) in adults, children, and poly-sensitized allergic patients. Meta-analyses indicate that SLIT-tablets have superior or similar efficacy compared with anti-allergic pharmacotherapies for seasonal AR and superior efficacy for perennial AR. SLIT-tablets have also demonstrated clinically relevant improvements of asthma, with significant reductions in the following: daily inhaled corticosteroid use, risk of asthma exacerbations, and asthma symptoms. SLIT-tablets are generally well tolerated, with a low risk of systemic allergic reactions. The most common treatment-related adverse events are mild-moderate oral reactions. Current evidence supports SLIT-tablets to be considered as an alternative or add-on treatment to pharmacotherapy for AR/C and asthma. Future SLIT developments may include early intervention to prevent the development or progression of allergic disease in children.

show abstract

Allergen immunotherapy: what’s new, what’s next?

Cited by 6 publications

References 19 publications

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

Single recombinant and purified major allergens and peptides

The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases

Contact Info

Product

Resources

About